BRCA1 and ovarian carcinoma: PARP inhibitors such as olaparib have revolutionised the treatment of first-line [1–3] and platinum-sensitive relapsed ovarian cancer [4–6], particularly in women who have BRCA1/2 mutations or evidence of homologous recombination deficient (HRD) tumours.